Business Standard

Sun Pharma rallies on FDA nod for cancer drug

USFDA have granted its subsidiary an approval for its ANDA for generic version of Doxil, Doxorubicin HCI liposome injection.

Related News

Sun Pharmaceutical Industries has rallied 4.4% to Rs 749 in morning trades after the company said US health regulators have approved a generic version of the drug Doxil.

“The U.S. Food and Drug Administration (USFDA) have granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) for generic version of Doxil, Doxorubicin HCI liposome injection,” said in a statement.

It will be available in 20 milligram and 50 milligram vials, it added.

Doxorubicin HCI liposome injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.

The stock opened at Rs 735 and touched high of Rs 752 on the NSE. A combined around 960,000 shares have changed hands on the counter in early morning deals on both the exchanges.

 

Read more on:   
|
|

Read More

UCO Bank slips on declining net

Shares of UCO Bank has slumped after the bank posted a sharp drop in net profit for the third quarter ended December 31, 2012.

Quick Links

 

Market News

Saffron crop washed out in Jammu & Kashmir floods

The crop is grown on small land holdings with an average size of 0.5 hectare by some 16,000 families in 226 villages

Iron ore prices surge to 4-year high at Odisha auction

The quoted price is nearly 45% more than the highest selling price of Rs 3,526 per tonne in the previous quarter (July-September) and 62% higher ...

FTIL opposes any move for NSEL amalgamation

FTIL says FMC proposal in this regard is not in public interest and ignores what has been found and accomplished in addressing the payments ...

Today's picks - 16 September 2014

Nifty, Bank Nifty, ITC, DLF & Tata Steel

Shemaroo IPO subscribed 27%

Shemaroo Entertainment's Rs 120 crore initial public offering (IPO) has received 27% subscription on day one

Back to Top